COVID-19
Conditions
Interventions
Control group:Take placebo for 21 days
Intervention group:Take Yiqi Zengmian prescription for 21 days
Sponsors
Xiyuan Hospital, China Academy of Chinese Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 59 Years
Inclusion criteria
Inclusion criteria: 1) Aged 18-59; 2) Those who have completed two doses of inactivated COVID-19 vaccine 6 months prior and have not received the third dose; 3) Agree to participate in this study.
Exclusion criteria
Exclusion criteria: 1) Those who have experienced transient and severe adverse reactions after vaccination, or had severe allergic reactions to vaccines, such as acute anaphylaxis, urticaria, skin eczema, dyspnea, angoneeurotic edema or abdominal pain, etc., which are judged by researchers be in high risk. 2) Those who are allergic to the ingredients in yiqi Zengmian Prescription. 3) Those who have fever, acute disease, severe chronic disease, in the acute onset of chronic disease. 4) Pregnant women and lactating women have a birth plan within 6 months of vaccination. 5) Those who have the history of convulsion, epilepsy, encephalopathy,Guillain-Barre syndrome or mental illness or family history, or uncontrolled epilepsy and other progressive neurological disorders. 6) Those who have been diagnosed as congenital or acquired immune deficiency, HIV infection, lymphoma, leukemia, or other autoimmune disease. 7) Those who have or suspected to have serious respiratory diseases, serious cardiovascular diseases, liver and kidney diseases, or malignant tumors. 8) Those who have the history of novel coronavirus infection. 9) Those who are taking or took drugs that may affect immune function, such as immunosuppressants or immunoenhancers or glucocorticoids (=10mg prednisone or other equivalent glucocorticoids), within one month prior to enrollment. 10) Researchers think it is not suitable for who to receive Traditional Chinese medicine.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| RBD specific antibody; | — |
Secondary
| Measure | Time frame |
|---|---|
| Neutralizing antibody;Adverse Event;Cytokines;Immune cell phenotype;TCM constitution questionnaire; | — |
Countries
China
Contacts
Public ContactQing Miao
Outcome results
None listed